Business Times Article: How Singapore can Lead Biopharma Innovation by INTERPAT & SAPI
INTERPAT supported SAPI (Singapore Association of Pharmaceutical Industries) and contributed to an IP article which highlights the importance of safeguarding Singapore’s attractiveness as a biopharmaceutical innovation hub through strong IP protection.
The Singapore Association of Pharmaceutical Industries (SAPI) aims to make innovative medicine accessible to patients in Singapore. We achieve this through a sustainable and valued partnership with healthcare professionals and providers, government and patient group stakeholders, and a reputation of consistent ethical behaviour.
for more information, visit their website at the following link: SAPI website